BioArctic AB Class B (B9A) AI Stock Analysis

BioArctic AB Class B

(Frankfurt:B9A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageVery low leverage limits financial risk and reduces the burden of interest or refinancing obligations. A strong equity base gives BioArctic greater flexibility to continue research, support partnered programs, and absorb earnings fluctuations without relying heavily on additional debt.

Negative Factors

Revenue contractionA sharp decline in the revenue run-rate weakens near-term visibility into the company’s recurring earning base. Because partnering revenue can depend on milestones and collaboration timing, sustained contraction would make it harder to plan investment and demonstrate consistent commercial progress.

BioArctic AB Class B (B9A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.57B
Dividend Yield: 0.66%
Average Volume (3M): 190
Price to Earnings (P/E): 260.7
Beta (1Y): 0.40
Revenue Growth: -44.33%
EPS Growth: -89.30%
Country: Germany
Employees: 150
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

BioArctic AB Class B Business Overview & Revenue Model

Company Description

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The compa...

BioArctic AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:B9A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SANION	77Outperform	SEK 1.54B	7.87	29.71%	―	24.98%	-31.44%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZCUR	49Neutral	SEK 882.54M	42.60	65.99%	―	―	―
SE:BINV	47Neutral	SEK 357.32M	-0.58	-128.54%	―	-83.67%	-50.29%
SE:IRLAB.A	46Neutral	SEK 310.81M	-3.20	-97.06%	―	4.74%	66.33%
SE:ALZ	43Neutral	SEK 112.04M	-1.62	-17.52%	―	-100.00%	20.94%

* Healthcare Sector Average

Performance Comparison

DE:B9A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:B9A	BioArctic AB Class B	28.26	2.95	11.67%
SE:BINV	BioInvent International AB	4.30	-28.85	-87.03%
SE:ALZ	Alzinova AB	0.34	-1.08	-75.98%
SE:ALZCUR	AlzeCure Pharma AB	6.36	4.50	241.02%
SE:SANION	Saniona AB	10.55	-5.75	-35.28%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	2.08	-0.28	-11.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BioArctic AB Class B AI Stock Analysis